Research Articles | Page 94 | Aplastic Anemia & MDS International Foundation

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Impaired proliferative potential of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway Mar 2014 Stem Cells Dev myelodysplastic syndromes (MDS)
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms Jul 2019 Surgical Pathology Clinic myelodysplastic syndromes (MDS)
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency Oct 2019 The Journal of Clinical Investigation paroxysmal nocturnal hemoglobinuria (PNH)
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial Jun 2019 The Lancet Haematology myelodysplastic syndromes (MDS)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes Jan 2020 The New England Journal of Medicine myelodysplastic syndromes (MDS)
Azacitidine in the management of patients with myelodysplastic syndromes. Dec 2012 Ther Adv Hematol myelodysplastic syndromes (MDS)
Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes Jan 2017 Ther Adv Hematol myelodysplastic syndromes (MDS)
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide Mar 2017 Ther Adv Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations Aug 2016 Ther Clin Risk Manag paroxysmal nocturnal hemoglobinuria (PNH)
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria Sep 2019 Therapeutic Advances in Hematology paroxysmal nocturnal hemoglobinuria (PNH)